Neil Kay, MD
Enriched profileProfessor of Medicine, Mayo Clinic College of Medicine and Science; Consultant, Division of Hematology, Department of Internal Medicine, Mayo Clinic · Mayo Clinic
Neil Kay is Professor of Medicine, Mayo Clinic College of Medicine and Science; Consultant, Division of Hematology, Department of Internal Medicine, Mayo Clinic at Mayo Clinic. OpenAlex indexes 1,015 publications with 31,307 citations (h-index 92); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Neil Kay, M.D., is Professor of Medicine, Mayo Clinic College of Medicine and Science. The public record shows 1,015 publications with 31,307 citations (h-index 92), centered on Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Immunodeficiency and Autoimmune Disorders. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 8 companies, 10 NIH-funded awards (2000–2025).
- Top research focus: Chronic Lymphocytic Leukemia Research
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 59 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 359.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
Sponsor: Mayo Clinic
- AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 27 Aug 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- Envista Holdings CorporationProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20232 payments
NIH funding
Updated 27 Aug 2026
10 NIH research awards on record, funded 2000–2025 per NIH RePORTER. The latest:
- REWIRING ONCOGENIC PATHWAYS TO INDUCE CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA
Stanford University
FY2026$661,135R01CA304428
Congress activity
Updated 27 Aug 2026
163 congress contributions (2004–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract 4228: Validation of the CLL treatment infection model (CLL-TIM) in patients with newly diagnosed chronic lymphocytic leukemia (CLL)
AACR Annual Meeting
AACR2026Co-author - Abstract 5064: Ancestry-associated epigenetic differences in chronic lymphocytic leukemia
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
New England Journal of Medicine
2019
Most-cited works
by citation count (OpenAlex)- 01
- 02Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaArticle1,632 citations2014
- 03ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic LeukemiaConference abstract907 citations2004
- 04Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaArticle745 citations2019
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
onclive.com/authors/neil-e-kay-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - Other
targetedonc.com/authors/neil-e-kay-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →targetedonc.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jewishpostandnews.ca ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jewishpostandnews.ca ↗
- Board certified
Internal Medicine and Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →md.com ↗
Editorial & leadership roles
journal and society appointments- Scientific Advisory Board (SAB) member
Lymphoma Research Foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lymphoma.org ↗ - Regular member
National Cancer Institute (NCI) Leukemia Steering Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jewishpostandnews.ca ↗ - Editor
Leukemia (Nature Publishing Group journal)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nature.com ↗
Awards & honors
honors on the public record- Rai Lecture recipient
Lymphoma, Leukemia & Myeloma Congress (2023), lecture titled "Pathobiology and Management of Double Refractory CLL"
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hmpglobal.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jewishpostandnews.ca ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jewishpostandnews.ca ↗
Media & interviews
press, podcasts and appearances- Researcher Spotlight feature
Lymphoma Research Foundation website
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lymphoma.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →patientpower.info ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Rick Nishimura, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic